Oleg Fedorov
PI, Group Head
- Biochemistry and Biophysics
Molecular Biophysics and Biochemistry group in CMD/TDI Oxford specialises on chemical probe discovery projects, especially in the field of Epigenetics and Ubiquitin system. Main target areas are acetyl-lysine reader domains and E3 ligases. The group supports the wide variety of screening assays developed for most of the targets. The in-depth characterization of drug candidates relies on a series of biophysical techniques established for accurate measurements of thermodynamics of and kinetic parameters of binding. The group also supports and extend the focused libraries of small molecular weight ligands for proteins of interest.
Recent publications
-
Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.
Journal article
Serafim RAM. et al, (2021), Journal of medicinal chemistry
-
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Journal article
Henderson SH. et al, (2021), Journal of medicinal chemistry, 64, 11709 - 11728
-
Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain
Journal article
Brand M. et al, (2021), Journal of Medicinal Chemistry
-
Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking.
Journal article
Schuller M. et al, (2020), bioRxiv
-
Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics
Journal article
The COVID Moonshot Consortium None. et al, (2020)